Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Heterocyclic carbon compounds containing a hetero ring...
Patent
1991-05-01
1993-09-21
Tsang, Cecilia
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Heterocyclic carbon compounds containing a hetero ring...
514 84, 514241, 514245, 514258, 514262, 514269, 514272, 514274, 514303, 514348, 544182, 544194, 544195, 544211, 544262, 544264, 544280, 544220, 544310, 544311, 544312, 544313, 544314, 544316, 544317, 544318, 544254, 546118, 546296, A61K 3153, C07D25300, C07D25100
Patent
active
052469310
ABSTRACT:
A compound of the formula: ##STR1## wherein A is a purin-9-yl group, a heterocyclic isostere of a purin-9-yl group, a pyrimidin-1-yl group or a heterocyclic isostere of a pyrimidin-1-yl group; E is hydrogen, --CH.sub.2 OH or --OH; and G and D are independently selected from hydrogen, C.sub.1 to C.sub.10 alkyl, --OH, --CH.sub.2 OH, --CH.sub.2 OR.sub.20 wherein R.sub.20 is C.sub.1 to C.sub.6 alkyl, --CH.sub.2 OC(O)R.sub.21 wherein R.sub.21 is C.sub.1 to C.sub.10 alkyl, --CH.sub.2 OC(O)CH(R.sub.22)(NHR.sub.23) wherein R.sub.22 is the side chain of any of the naturally occurring amino acids and R.sub.23 is hydrogen or --C(O)CH(R.sub.24)(NH.sub.2) wherein a R.sub.24 is the side chain of any of the naturally occurring amino acids, --CH.sub.2 SH, --CH.sub.2 Cl, --CH.sub.2 F, --CH.sub.2 Br, --CH.sub.2 I, --C(O)H, --CH.sub.2 CN, --CH.sub.2 N.sub.3, --CH.sub.2 NR.sub.1 R.sub.2, --CO.sub.2 R.sub.1, --CH.sub.2 CH.sub.2 OH, --CH.sub.2 CH.sub.2 OR.sub.20 wherein R.sub.20 is as defined above, --CH.sub.2 CH.sub.2 OC(O)R.sub.21 wherein R.sub.21 is as defined above, --CH.sub.2 CH.sub.2 OC(O)CH(R.sub.22)(NHR.sub.23) wherein R.sub.22 and R.sub.23 are as defined above, --CH.sub.2 CH.sub.2 PO.sub.3 H.sub.2, --CH.sub.2 OPO.sub.3 H.sub.2, --OCH.sub.2 PO.sub.3 H.sub.2 and --CH.sub.2 CO.sub.2 R.sub.3 wherein R.sub.1 and R.sub.2 are independently selected from hydrogen and C.sub.1 to C.sub.10 alkyl and R.sub.3 is hydrogen, C.sub.1 to C.sub.10 alkyl, carboxyalkyl or aminoalkyl; or a pharmaceutically acceptable salt thereof.
REFERENCES:
patent: 3923792 (1975-12-01), Albrecht et al.
patent: 4016267 (1977-04-01), Albrecht et al.
patent: 4508898 (1985-04-01), Ogilvie
patent: 4617304 (1986-10-01), Ashton et al.
patent: 4644001 (1987-02-01), Kjellin et al.
patent: 4782062 (1988-11-01), Tolman et al.
patent: 4788181 (1988-11-01), Driscoll et al.
patent: 4918075 (1990-04-01), Zahler et al.
patent: 4968690 (1990-11-01), Marquez et al.
patent: 4975434 (1990-12-01), Marquez et al.
patent: 5126345 (1992-06-01), Slusarchyk et al.
Kim et al., "Potential Anti-AIDS Drugs", J. Med. Chem., 1987, 30, 862-866.
Beauchamp et al., "Effect Of Acyclic Pyrimidines . . . , " J. Med. Chem., Jan. 31, 1988, 144-149.
Ogilvie et al., "Synthesis of 5-Substituted . . . " Nucleosides and Nucleotides, 2(2), 147-154 (1983).
Allen et al., "Acyclic Pyrimidine Analogues . . . , " Chemotherapy, 31, 151-159 (1985).
Myska et al., "Azauridine In Viral Eye Infections", Lancet, Jun. 3, 1967, pp. 1230-1231.
Rada et al., "Antiviral Action and Selectivity Of 6-Azauridine", Ann. N.Y. Acad. Sci., vol. 214, (1977), pp. 410-447.
Rada, "The Effect Of Cell-Free Extracts . . . " Ann. N.Y. Acad. Sci., vol. 173, 176-184 (1970).
Temple, et al., J. Me. Pharm. Chem. 5 866 (1962).
Marquez, et al., Medicinal Researchy Reviews, 6 1-40 (1986).
Garmaise David L.
Hannick Steven M.
Norbeck Daniel W.
Pariza Richard J.
Plattner Jacob J.
Bristol--Myers Squibb Company
Davis Stephen B.
Tsang Cecilia
LandOfFree
Carbocyclic nucleoside analogs does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Carbocyclic nucleoside analogs, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Carbocyclic nucleoside analogs will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-1049935